D. E. Shaw & Co., Inc. Keros Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$100 Billion
Q1 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 1,263,130 shares of KROS stock, worth $18.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,263,130

Previous 12,099 10339.95%

Holding current value

$18.1 Million

Previous $191,000 6638.74%

% of portfolio

0.01%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$10.15 - $16.1 $12.7 Million - $20.1 Million	1,251,031 Added 10339.95%	1,263,130 $12.9 Million
Q4 2024 Feb 14, 2025	SELL	$15.64 - $70.0 $2.72 Million - $12.2 Million	-174,189 Reduced 93.51%	12,099 $191,000
Q3 2024 Nov 14, 2024	BUY	$41.68 - $58.07 $441,516 - $615,135	10,593 Added 6.03%	186,288 $10.8 Million
Q2 2024 Aug 14, 2024	BUY	$44.58 - $66.89 $6.99 Million - $10.5 Million	156,821 Added 830.88%	175,695 $8.03 Million
Q1 2024 May 15, 2024	BUY	$41.26 - $70.48 $778,741 - $1.33 Million	18,874 New	18,874 $1.25 Million
Q1 2023 May 15, 2023	BUY	$41.44 - $59.32 $1.29 Million - $1.84 Million	31,032 New	31,032 $1.33 Million
Q2 2022 Aug 15, 2022	BUY	$26.03 - $67.04 $548,087 - $1.41 Million	21,056 New	21,056 $582,000
Q2 2021 Aug 16, 2021	SELL	$42.4 - $70.11 $1.11 Million - $1.83 Million	-26,142 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$54.0 - $75.28 $1.57 Million - $2.19 Million	-29,060 Reduced 52.64%	26,142 $1.61 Million
Q4 2020 Feb 16, 2021	BUY	$36.0 - $82.74 $1.99 Million - $4.57 Million	55,202 New	55,202 $3.89 Million

Others Institutions Holding KROS

# of Institutions

177

Shares Held

36.5M

Call Options Held

938K

Put Options Held

1.39M

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $370M
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account